Stoke Therapeutics (STOK)
NASDAQ:STOK
Want to see STOK full AI Analyst Report?
STOK Stock Chart & Stats
$37.27
-$0.34(-3.65%)
At close: 4:00 PM EST
$37.27
-$0.34(-3.65%)
Day’s Range― - ―
52-Week Range$11.17 - $40.22
Previous CloseN/A
Volume337.58K
Average Volume (3M)535.04K
Market Cap
$1.83B
Enterprise Value$1.77B
Total Cash (Recent Filing)$343.55M
Total Debt (Recent Filing)$3.42M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Aug 10, 2026EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.83
Shares Outstanding62,281,654
10 Day Avg. Volume497,831
30 Day Avg. Volume535,036
Financial Highlights & Ratios
PEG Ratio2.94
Price to Book (P/B)5.33
Price to Sales (P/S)10.19
P/FCF Ratio41.85
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue55.26
Enterprise Value/Gross Profit61.16
Enterprise Value/Ebitda-10.80
Forecast
1Y Price Target
$47.83Price Target Upside28.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.22
Revenue Forecast (FY)$26.38M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetMinimal debt and a sizable equity base provide durable financial flexibility to fund multi-year clinical programs, reduce refinancing risk, and allow management to prioritize R&D execution over near-term cash preservation, supporting program continuity through pivotal stages.
High Gross Margins On RevenueHistorically very high gross margins for its RNA-based programs suggest scalable cost economics for any future product sales, enabling attractive long-term operating leverage as revenue grows and supporting sustainable profitability once fixed R&D overheads are absorbed.
Strengthened R&D/regulatory OversightAdding an experienced regulatory and drug-development leader to chair R&D materially improves governance and regulatory strategy at a pivotal Phase 3 stage, reducing execution and approval risk and improving long-term odds of successful commercialization.
Bears Say
Sharp Revenue Decline And Deep LossesSevere revenue contraction and persistently large operating losses reflect an unstable revenue base and an operating cost structure misaligned with current sales, creating an extended path to self-sustaining profitability and raising the bar for future commercial viability.
Elevated Cash Burn And Negative Cash FlowSustained large operating and free cash outflows imply ongoing reliance on external financing, heightening dilution risk and limiting flexibility to pursue parallel development programs without successful milestone events or additional capital.
No Meaningful Recurring Product Revenue; Funding RelianceThe business lacks product-derived recurring revenue, depending on collaborations, milestone payments, and equity raises. This structural revenue unpredictability increases execution risk and the likelihood of future dilution until a commercial product is established.
Stoke Therapeutics News
STOK FAQ
What was Stoke Therapeutics’s price range in the past 12 months?
Stoke Therapeutics lowest stock price was $11.17 and its highest was $40.22 in the past 12 months.
What is Stoke Therapeutics’s market cap?
Stoke Therapeutics’s market cap is $1.83B.
When is Stoke Therapeutics’s upcoming earnings report date?
Stoke Therapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 58 days.
How were Stoke Therapeutics’s earnings last quarter?
Stoke Therapeutics released its earnings results on May 07, 2026. The company reported -$0.79 earnings per share for the quarter, beating the consensus estimate of -$0.808 by $0.018.
Is Stoke Therapeutics overvalued?
According to Wall Street analysts Stoke Therapeutics’s price is currently Undervalued.
Does Stoke Therapeutics pay dividends?
Stoke Therapeutics does not currently pay dividends.
What is Stoke Therapeutics’s EPS estimate?
Stoke Therapeutics’s EPS estimate is -0.77.
How many shares outstanding does Stoke Therapeutics have?
Stoke Therapeutics has 62,281,654 shares outstanding.
What happened to Stoke Therapeutics’s price movement after its last earnings report?
Stoke Therapeutics reported an EPS of -$0.79 in its last earnings report, beating expectations of -$0.808. Following the earnings report the stock price went up 0.305%.
Which hedge fund is a major shareholder of Stoke Therapeutics?
Currently, no hedge funds are holding shares in STOK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stoke Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.83 (28.34% Upside)
$47.83 (28.34% Upside)
Blogger Sentiment
Bullish
STOK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 41.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $552.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
152.28%
12-Months-Change
Fundamentals
Return on Equity
-48.84%
Trailing 12-Months
Asset Growth
8.94%
Trailing 12-Months
Company Description
Stoke Therapeutics
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
STOK Company Deck
STOK Earnings Call
Q1 2026
0:00 / 0:00
STOK Stock 12 Month Forecast
Average Price Target
$47.83
▲(28.34% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Xeris Pharmaceuticals
―
―
Rapport Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
7.11% Insiders
18.33% Mutual Funds
53.98% Other Institutional Investors
6.72% Public Companies and
Individual Investors